FI960227A7 - 2,8-disubstituoidut kinatsolinonit - Google Patents

2,8-disubstituoidut kinatsolinonit Download PDF

Info

Publication number
FI960227A7
FI960227A7 FI960227A FI960227A FI960227A7 FI 960227 A7 FI960227 A7 FI 960227A7 FI 960227 A FI960227 A FI 960227A FI 960227 A FI960227 A FI 960227A FI 960227 A7 FI960227 A7 FI 960227A7
Authority
FI
Finland
Prior art keywords
quinazolinones
disubstituted
disubstituted quinazolinones
Prior art date
Application number
FI960227A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI960227A0 (fi
Inventor
Fred Robert Heiker
Ulrich Niewoehner
Wolfgang Hartwig
Helmuth Schuetz
Erwin Bischoff
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI960227A0 publication Critical patent/FI960227A0/fi
Publication of FI960227A7 publication Critical patent/FI960227A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/92—Oxygen atoms with hetero atoms directly attached to nitrogen atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI960227A 1995-01-19 1996-01-17 2,8-disubstituoidut kinatsolinonit FI960227A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501481A DE19501481A1 (de) 1995-01-19 1995-01-19 2,8-Disubstituierte Chinazolinone

Publications (2)

Publication Number Publication Date
FI960227A0 FI960227A0 (fi) 1996-01-17
FI960227A7 true FI960227A7 (fi) 1996-07-20

Family

ID=7751829

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960227A FI960227A7 (fi) 1995-01-19 1996-01-17 2,8-disubstituoidut kinatsolinonit

Country Status (32)

Country Link
US (1) US5721238A (cs)
EP (1) EP0722937A1 (cs)
JP (1) JPH08253457A (cs)
KR (1) KR960029325A (cs)
CN (1) CN1134417A (cs)
AR (1) AR006738A1 (cs)
AU (1) AU704102B2 (cs)
BG (1) BG100293A (cs)
BR (1) BR9600148A (cs)
CA (1) CA2167345A1 (cs)
CO (1) CO4700522A1 (cs)
CZ (1) CZ16796A3 (cs)
DE (1) DE19501481A1 (cs)
EE (1) EE9600019A (cs)
FI (1) FI960227A7 (cs)
HR (1) HRP960004A2 (cs)
HU (1) HUP9600114A3 (cs)
IL (1) IL116770A (cs)
IN (1) IN184956B (cs)
MA (1) MA23780A1 (cs)
NO (1) NO307513B1 (cs)
NZ (1) NZ280831A (cs)
PE (1) PE66696A1 (cs)
PL (1) PL312352A1 (cs)
RO (1) RO117451B1 (cs)
RU (1) RU2158733C2 (cs)
SG (1) SG34377A1 (cs)
SK (1) SK7796A3 (cs)
SV (1) SV1996000005A (cs)
TR (1) TR199600029A2 (cs)
YU (1) YU1496A (cs)
ZA (1) ZA96397B (cs)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US20020025969A1 (en) * 1997-07-09 2002-02-28 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6110489A (en) * 1998-05-01 2000-08-29 Cutler; Neal R. Use of quinolines and quinolones to treat male erectile dysfunction
US6132757A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6194433B1 (en) * 1998-10-05 2001-02-27 Neal R. Cutler Sexual dysfunction in females
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6132753A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6303135B1 (en) 1999-07-08 2001-10-16 Neal R. Cutler Use of quinolines and quinolones to treat male erectile dysfunction
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
KR100610131B1 (ko) * 2000-09-06 2006-08-09 다나베 세이야꾸 가부시키가이샤 경구 투여용 제제
US6562838B2 (en) * 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
ATE472319T1 (de) 2001-02-15 2010-07-15 Mitsubishi Tanabe Pharma Corp Tabletten, die in der mundhöhle schnell zerfallen
HUP0500117A3 (en) * 2001-11-30 2008-03-28 Pfizer Prod Inc Processes for the preparation of substituted quinazoline derivatives for the treatment of abnormal cell growth
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
CA2542007C (en) 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
CA2506897A1 (en) * 2002-12-27 2004-07-15 Tibotec Bvba Fluorogenic enzyme substrates and methods of preparation
AU2005212092B2 (en) * 2004-02-13 2011-01-20 Msd K.K. Fused-ring 4-oxopyrimidine derivative
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
KR101129868B1 (ko) * 2006-10-04 2012-04-12 화이자 프로덕츠 인코포레이티드 칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체
WO2008083491A1 (en) 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
JP6393037B2 (ja) 2010-09-15 2018-09-19 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤および使用方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9708367B2 (en) * 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US20170044127A1 (en) * 2014-01-23 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin derivatives
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
CN110590769B (zh) * 2019-06-13 2021-09-24 中山大学 一对喹唑啉酮生物碱对映体及其制备方法和应用
WO2024026424A1 (en) * 2022-07-27 2024-02-01 Black Diamond Therapeutics, Inc. Quinazolinone derivatives as and related uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS6136273A (ja) * 1984-07-26 1986-02-20 Mitsubishi Yuka Yakuhin Kk ２−フエニルアルキル−４（３ｈ）−キナゾリノン誘導体
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof

Also Published As

Publication number Publication date
EP0722937A1 (de) 1996-07-24
NO960222L (no) 1996-07-22
NO960222D0 (no) 1996-01-18
IN184956B (cs) 2000-10-07
PL312352A1 (en) 1996-07-22
SK7796A3 (en) 1996-08-07
ZA96397B (en) 1996-08-28
RU2158733C2 (ru) 2000-11-10
HU9600114D0 (en) 1996-03-28
IL116770A0 (en) 1996-05-14
CA2167345A1 (en) 1996-07-20
HUP9600114A3 (en) 2000-03-28
JPH08253457A (ja) 1996-10-01
CN1134417A (zh) 1996-10-30
SV1996000005A (es) 1997-03-11
AU704102B2 (en) 1999-04-15
EE9600019A (et) 1996-08-15
PE66696A1 (es) 1997-03-09
SG34377A1 (en) 1996-12-06
AR006738A1 (es) 1999-09-29
US5721238A (en) 1998-02-24
HRP960004A2 (en) 1998-02-28
CZ16796A3 (en) 1996-08-14
RO117451B1 (ro) 2002-03-29
CO4700522A1 (es) 1998-12-29
KR960029325A (ko) 1996-08-17
YU1496A (sh) 1998-09-18
AU4098096A (en) 1996-07-25
TR199600029A2 (tr) 1996-08-21
MA23780A1 (fr) 1996-10-01
DE19501481A1 (de) 1996-07-25
NZ280831A (en) 1996-10-28
BG100293A (en) 1996-07-31
FI960227A0 (fi) 1996-01-17
HUP9600114A2 (en) 1996-12-30
IL116770A (en) 2000-08-31
NO307513B1 (no) 2000-04-17
BR9600148A (pt) 1998-01-06

Similar Documents

Publication Publication Date Title
FI960227A0 (fi) 2,8-disubstituoidut kinatsolinonit
DK0817775T3 (da) Quinazolinderivater
DK0823900T3 (da) Quinazolinderivater
FI950715A0 (fi) Ytmikromekanisk, symmetrisk tryckskillnadsgivare
DE69618634D1 (de) 1,4-benzodioxin-derivate
BR9609884A (pt) N-aril- 1,2,4-triazolin-5-onas
DK0874814T3 (da) 25-hydroxy-16-en-26,27-bishomo-cholecalciferoler
EP0811014A4 (en) Novel bacteriocin piscicolin 126
DE59601292D1 (de) Schutzplankenanordnung
DE59605552D1 (de) Oberbaukonstruktion
NO962931D0 (no) N,N-Dietyl-8,8-dipropyl-2-azaspiro[4,5Ådecan-2-propanamindimaleat
ES1032571Y (es) Gafa,
BR9610047A (pt) 1,3,4-oxadiazolin-2-onas
KR970015897U (ko) 조합식 상의
UA12U (uk) Крапельниця
NO950272D0 (no) Spinnedyse
ES1031427Y (es) Peonza mejorada.
FI952912A0 (fi) Traedcylinder, gripelement med traedrotsprincip
FI951203A0 (fi) Rullformningsmaskin
KR960038266U (ko) 개량 권척
KR970028193U (ko) 개량신문
FI952416A0 (fi) Distributionsanordning foer vaetska, speciellt tvaettvaetska foer vindrutor
FI950956A0 (fi) Luftkabel, saosom haengspiralkabel